From: Cost utility and budget impact analysis of dexamethasone compared with bortezomib and lenalidomide for the treatment of second line multiple myeloma from a South African public health perspective
Health state
Utility value
Source
Pre-progression
0.81
Van Agthoven et al. [32]
Pre-progression after 2Â years
0.77
Progression
0.64
Dead
0
